Merck & Co., Inc. Defined Benefit Plan, Effect of One Percentage Point Decrease on Accumulated Postretirement Benefit Obligation
Merck & Co., Inc. (MRK) reported Defined Benefit Plan, Effect of One Percentage Point Decrease on Accumulated Postretirement Benefit Obligation of $74.00 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-27.
Discontinued › Notes › Compensation Related Costs › Defined Benefit Plan › Defined Benefit Plan, Effect of One-Percentage-Point Change in Assumed Health Care Cost Trend Rate
us-gaap:DefinedBenefitPlanEffectOfOnePercentagePointDecreaseOnAccumulatedPostretirementBenefitObligation1 · last filed 2019-02-27
- Merck & Co., Inc. defined benefit plan, effect of one percentage point decrease on accumulated postretirement benefit obligation for fiscal 2018 was $74.00M, a 28.85% decline from fiscal 2017.
- Merck & Co., Inc. defined benefit plan, effect of one percentage point decrease on accumulated postretirement benefit obligation for fiscal 2017 was $104.00M, a 8.77% decline from fiscal 2016.
- Merck & Co., Inc. defined benefit plan, effect of one percentage point decrease on accumulated postretirement benefit obligation for fiscal 2016 was $114.00M, a 78.13% increase from fiscal 2015.
- Merck & Co., Inc. defined benefit plan, effect of one percentage point decrease on accumulated postretirement benefit obligation for fiscal 2015 was $64.00M, a 81.12% decline from fiscal 2014.
| Period end | Defined Benefit Plan, Effect of One Percentage Point Decrease on Accumulated Postretirement Benefit Obligation 12 month |
|---|---|
| 2018-12-31 | $74.00M 10-K · filed 2019-02-27 |
| 2017-12-31 | $104.00M 10-K · filed 2018-02-27 |
| 2016-12-31 | $114.00M 10-K · filed 2017-02-28 |
| 2015-12-31 | $64.00M 10-K · filed 2016-02-26 |
| 2014-12-31 | $339.00M 10-K · filed 2015-02-27 |
| 2013-12-31 | $262.00M 10-K · filed 2014-02-27 |
| 2012-12-31 | $324.00 10-K · filed 2013-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |